

Table 2 Association between incident pseudogout and prescription of individual oral bisphosphonates within the preceding 60 days

Bisphosphonate	Pseudogout cases n (%)	Controls n (%)	Unadjusted IRR (95% CI)	Adjusted IRR (95%CI) *
Alendronic acid	84 (4.2)	211 (2.6)	1.65 (1.26, 2.12)	1.36 (1.03, 1.79)
Disodium etidronate	11 (0.6)	22 (0.3)	2.00 (0.97, 4.12)	1.44 (0.67, 3.09)
Ibandronic acid	4 (0.2)	20 (0.3)	0.80 (0.27, 2.34)	0.64 (0.21, 1.98)
Risedronate sodium	22 (1.1)	53 (0.7)	1.68 (1.01, 2.81)	1.22 (0.71, 2.10)
Sodium clodronate	2 (0.1)	2 (<0.1)	4.00 (0.56, 28.40)	1.37 (0.13, 14.93)
Tiludronate disodium	0 (0.0)	0 (0.0)	-	-

CI, confidence interval; IRR, incidence rate ratio

* adjusted for hyperparathyroidism, osteoarthritis, rheumatoid arthritis, and prescriptions for diuretics and oral corticosteroids